The announcement of new IDMP guidelines in February this year has left the industry with much food for thought. The first implementation guide is to be shortly followed by a second version, by which point companies must have an actionable plan in place to ensure they maintain compliance whilst also further preparing for future global harmonisation. We reached out to some of the Global Pharmaceutical Regulatory Affairs speakers with some quick-fire questions to gauge their thoughts on the new guidelines, the impact of COVID-19 and common obstacles that industry are currently facing. To download the exclusive article, simply log in or register free for a Informa Connect account, which will give you access to all our exclusive premium content.